Key Insights on Pfizer’s Financial Performance

⚡Total Revenue declined by 20.66% from 2016 to 2020, with a YoY increase of 1.76% in 2020

⚡ Cost of Sales declined by 29.50% from 2016 to 2020 with a YoY increase of 5.34% in 2020

⚡Avg of 36.63% and 59.38% of total expenses was spent on R&D expenses and selling, marketing & admin expense respectively in 2020

⚡Net Income increased by 33.22% from 2016 to 2020, with a YoY decline of 40.80% in 2020

⚡ Liquidity: Pfizer has maintained an avg of 9.51% of total Assets in highly Liquid Assets for the 5 years period.

⚡ Return on Equity: Pfizer slightly increased the returns to stockholders from 12.10% in 2016 to 15.20% in 2020, and recorded YoY decline of 40.86% in 2020

⚡Leverage: Pfizer has a moderate gearing ratio of 62.8% in 2020

Source : Pfizer Annual Report